What Happens If a Cancer Patient Gets the Flu?

A cancer patient who catches influenza faces roughly two to three times the risk of hospitalization or death compared to someone without cancer, and the infection can cascade into complications that derail ongoing treatment. The reasons go beyond a weakened immune system: certain cancer types, specific therapies, and even the timing of treatment all shape how dangerous the flu becomes. Understanding those risks changes real decisions about vaccination, antiviral treatment, and who else in the household needs a flu shot.

Why the Flu Hits Cancer Patients Harder

The immune system of a person undergoing cancer treatment is fighting on two fronts. Chemotherapy, radiation, and targeted therapies can all suppress the bone marrow’s ability to produce the white blood cells that normally fight off infections. When influenza arrives in that setting, the body mounts a weaker and slower defense, giving the virus more time to spread from the upper airways into the lungs and beyond.

A large propensity-matched study of hospitalized cancer patients found that those who also had influenza had higher rates of nearly every serious complication: pneumonia occurred in about 18% versus 13% of matched cancer patients without flu, sepsis in roughly 20% versus 9%, and acute kidney injury in about 20% versus 18%. In-hospital mortality was also higher, at around 5.4% compared to 4.2% in the non-flu group.¹ Neutropenia, which leaves patients essentially defenseless against bacteria, was more than twice as common in cancer patients with flu than in those without it.

Bacterial co-infection is a major reason flu becomes life-threatening. One review found that 87% of cancer patients with serious influenza developed bacterial complications, and half of those involved pneumococcal pneumonia.² The virus damages the airway lining, and with fewer immune cells available to clean up, bacteria take hold quickly. Fatality rates in cancer patients hospitalized for serious influenza-related infections have been reported in the range of 9 to 10%.³

Blood Cancers Versus Solid Tumors

Not all cancers carry the same flu risk, and the gap is dramatic. A large matched cohort study using English health records found that survivors of blood cancers (leukemia, lymphoma, myeloma) had roughly 15 times the risk of severe influenza outcomes compared to people without any cancer history. For those within one to five years of diagnosis, the risk was nearly 30 times higher.⁴

Survivors of non-blood cancers had a much smaller elevation in risk, roughly double for those in the first five years after diagnosis, with no measurable increase for longer-term survivors. The reason for the divide is straightforward: blood cancers and their treatments directly attack the immune cell populations responsible for fighting viruses. Chemotherapy for a breast tumor may temporarily lower white blood cell counts, but treatments for leukemia or lymphoma can wipe out entire lines of immune defense for months or years.

A study of 190 patients with blood cancers who caught influenza found that 42% developed lower respiratory tract infections and 16% died within 60 days. Patients with leukemia specifically, those who were low on oxygen when diagnosed, and those who had simultaneous bacterial or fungal infections were at the highest risk of death.⁵ The takeaway is that the type of cancer matters at least as much as the fact of having cancer at all.

How the Flu Disrupts Cancer Treatment

Even when the flu itself resolves without serious complications, it can cause real harm by forcing delays in chemotherapy. Oncologists typically require patients to meet certain blood count thresholds before each chemotherapy cycle. A flu infection drops those counts, and it can take weeks for them to recover, especially when the immune system was already under strain.

A prospective study of over 500 cancer patients found that about 39% experienced at least one chemotherapy delay, with fever or infection accounting for roughly a quarter of those delays. Upper respiratory infections specifically were a strong independent risk factor, increasing the odds of a chemotherapy delay by nearly double, and when looking only at delays caused directly by infection, upper respiratory infections raised the odds more than fivefold.⁶

In children with cancer, the disruption is similarly common. A study of pediatric oncology patients found that 40% experienced a delay in their scheduled chemotherapy as a direct result of influenza infection.⁷ These delays are not trivial scheduling inconveniences. For cancers where treatment timing is critical, interruptions can affect how well the cancer responds to therapy. The flu is not just making the patient sicker in the short term; it may be undermining the treatment plan itself.

Why Diagnosis Is Trickier Than It Sounds

One underappreciated problem is that flu in a cancer patient can be easy to miss or mistake for something else. The classic flu symptoms like fever, body aches, and fatigue overlap heavily with common side effects of chemotherapy. A patient on treatment who develops a fever and feels terrible may assume it is the chemo, and their care team may initially think so too.

Flu season also coincides with the time when many other respiratory viruses are circulating, adding to the diagnostic confusion. The illness presents with nonspecific symptoms of upper respiratory infection at a time when similar bugs are common in the community, making the diagnosis genuinely challenging.⁸ This matters because early antiviral treatment works best when started within the first 48 hours, and every hour of diagnostic delay chips away at that window.

Cancer centers increasingly use rapid molecular testing for influenza during flu season, especially for patients presenting with any respiratory symptoms. A cancer patient with a new cough or fever during flu season should bring it up with their oncology team rather than assuming it is a treatment side effect. The cost of a missed flu diagnosis is much higher in this population than in a healthy adult.

Antiviral Treatment and the Problem of Prolonged Shedding

When flu is caught, antiviral drugs like oseltamivir (Tamiflu) are the standard treatment. At one ambulatory cancer center, 83% of cancer outpatients diagnosed with influenza were prescribed oseltamivir. But only about a third of patients were prescribed the drug within the ideal 48-hour window from symptom onset, partly because of the diagnostic delays described above.⁹ Even when treatment came late, oncologists generally still prescribed antivirals because the consequences of untreated flu in this population are severe enough to justify treatment beyond the textbook window.

A complication specific to immune-suppressed patients is prolonged viral shedding. In healthy adults, the body clears influenza within about a week. In cancer patients, especially those with severely suppressed immune systems, the virus can persist for weeks. A study of immunocompromised patients found that 15% were still shedding the virus more than 14 days after diagnosis, despite receiving antiviral therapy.¹⁰ That prolonged shedding does two things: it extends the period the patient can infect others, and it creates a breeding ground for antiviral-resistant strains. In that same study, about 7% of immunocompromised patients developed oseltamivir resistance during treatment.

Antiviral resistance is a real concern in oncology settings. Immunocompromised patients are at higher risk of developing resistance because the virus replicates for longer periods, giving it more chances to mutate.¹¹ When resistance emerges, treatment options narrow considerably. This is why infection control measures in cancer wards are so strict during flu season, and why preventing flu in the first place carries outsized importance.

Flu Vaccination During Cancer Treatment

You might assume there is no point in vaccinating someone whose immune system is suppressed, but the evidence says otherwise. The immune response is weaker, and that is well established. One study found that breast cancer patients on chemotherapy had significantly lower antibody responses to the flu vaccine compared to healthy controls.¹² A Cochrane review of children receiving chemotherapy found that their four-fold antibody rise rates ranged from 38% to 65%, compared to 53% to 89% in healthy children.¹³ The important finding from that same review, though, is that no life-threatening or persistent adverse effects were reported among nearly 400 vaccinated pediatric oncology patients. The vaccine is safe in this group even when it is less effective.

A reduced immune response is not the same as no response. Even partial protection can mean the difference between a mild upper respiratory infection and a hospital stay with pneumonia. Guidelines from oncology societies generally recommend that cancer patients receive the inactivated flu vaccine annually, with the understanding that the protection will be imperfect. Live attenuated vaccines (the nasal spray type) are avoided because of the theoretical risk of causing infection in a suppressed immune system.

When in the Chemo Cycle to Get Vaccinated

Timing the flu shot around chemotherapy cycles turns out to matter quite a bit. A classic finding showed that only 50% of patients vaccinated at the same time as chemotherapy administration had a meaningful antibody response, compared to 93% of those vaccinated between chemotherapy courses.¹⁴

More recent research has added nuance to this. A study of breast cancer patients found that those vaccinated earlier in their chemotherapy cycle (around day 5 after chemo) had significantly higher antibody levels than those vaccinated later (around day 16). The geometric mean antibody titers for the H1N1 strain, for instance, were more than four times higher in the early group.¹⁵ This suggests that the immune system is more receptive in the early recovery window after a chemotherapy dose, before the next wave of immune suppression hits.

There is also some evidence that higher-dose flu vaccines may help compensate for the blunted immune response. A pilot trial in cancer patients younger than 65 found that high-dose influenza vaccine produced better seroconversion rates and higher antibody levels for multiple flu strains compared to the standard dose.¹⁶ High-dose flu vaccines are already approved for older adults, and this research suggests they could help younger cancer patients too, though larger trials are still needed.

Flu Shots and Immunotherapy

Immunotherapy drugs, particularly checkpoint inhibitors, work by releasing the brakes on the immune system so it can attack cancer. That mechanism raised a reasonable concern: would a flu vaccine, which stimulates the immune system, cause an over-reaction in patients already on drugs designed to rev up immune activity? The worry was that vaccination might trigger or worsen immune-related side effects like inflammation of the thyroid, liver, lungs, or skin.

The evidence so far is reassuring. A systematic review with meta-analysis concluded that influenza vaccination is safe in patients receiving checkpoint inhibitors, does not increase the risk of immune-related adverse events, and may actually improve survival.¹⁷ A separate study of 370 cancer patients on checkpoint inhibitors found that about 20% experienced a new immune-related adverse event, but the rates and severity were no higher than what is typically seen in published reports of patients on these drugs who were not vaccinated.¹⁸ In other words, the side effects tracked with what the drugs do on their own, not with the vaccine.

This is genuinely good news, because immunotherapy patients are still at increased infection risk and benefit from vaccination. The theoretical concern about over-stimulation has not materialized in the data collected so far.

Some Therapies Make Vaccination Nearly Useless

Not all cancer treatments suppress vaccine response equally. Rituximab, a drug used for certain lymphomas and autoimmune conditions, deserves special mention because it specifically destroys B cells, the immune cells that produce antibodies. In a study of rituximab-treated patients, only 16% achieved a meaningful antibody response to the flu vaccine.¹⁹ That is a near-failure rate, and it means these patients depend almost entirely on the people around them being vaccinated.

B cell recovery after rituximab can take six months or longer. Oncologists sometimes try to time the flu vaccine for as late as possible after a rituximab dose to give B cells a chance to repopulate, but the practical window is often tight. For patients in active treatment with rituximab or similar B-cell-depleting therapies, the vaccine may be given anyway because the downside risk is negligible, but the expectation of meaningful protection has to be tempered.

Protecting Cancer Patients Through Household Vaccination

Because cancer patients often cannot mount a full immune response to vaccination themselves, the vaccination status of everyone around them matters enormously. This concept, sometimes called cocooning, means that family members, caregivers, and anyone sharing a household with a cancer patient should be fully up to date on their flu shots.

The data suggest this message is not getting through. A study found that while about 59% of cancer patients themselves were vaccinated, the rate among their family members was under 45%.²⁰ That gap is a real vulnerability. A flu virus brought home by an unvaccinated child or partner can be a far greater threat to the cancer patient than it would be in any other household. Research on following recommended vaccination schedules for both patients and their close contacts has shown reductions in hospitalizations, treatment delays, and deaths.²¹

Beyond vaccination, basic hygiene measures during flu season carry more weight for cancer households. Hand-washing, staying away from the patient when symptomatic, and wearing a mask if illness cannot be avoided are all meaningful layers of protection. Healthcare workers in oncology settings follow similar protocols, and cancer centers often restrict visitation during peak flu season.

The Economic and Hospital Burden

Flu-related hospital stays in cancer patients tend to be longer and more resource-intensive than in the general population. The propensity-matched study mentioned earlier found that hospitalized cancer patients with flu stayed an average of 6.3 days compared to 5.6 days for matched cancer patients without flu.¹ A broader study of hospital costs for influenza-like illness in adults over 50 found that patients with cancer and renal failure had the highest mean hospitalization costs.²²

Those numbers do not capture the full picture. Cancer patients who are hospitalized for flu may need to postpone surgeries, delay radiation schedules, or extend the overall duration of their treatment plan. Each of those downstream effects has its own cost, both financial and in terms of cancer outcomes. The hospital stay itself is just the visible portion of a much larger disruption.

For patients treated in ambulatory (outpatient) cancer settings, outcomes from flu tend to be better than those requiring inpatient care. One cancer center found that among 133 outpatients diagnosed with flu, about 7% progressed to lower respiratory tract infection and about 8% required hospitalization.⁹ Those rates are still notably higher than in the general population, but they illustrate that early recognition and outpatient antiviral treatment can keep many cancer patients out of the hospital. The patients who do get admitted tend to be those with the deepest immune suppression, existing lung problems, or bacterial co-infections on top of the flu.